Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model

Pharmaceutical Research

Volumn 18, Issue 9, 2001, Pages 1315-1319

  Suarez, Sandra ^a   O’Hara, Patrick ^a   Kazantseva, Masha ^a   Newcomer, Christian E ^b   Hopfer, Roy ^c   McMurray, David N ^d   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Low dose aerosol infection; Pulmonary tuberculosis; Rifampicin loaded poly(lactide co glycolide) microspheres

Indexed keywords

MICROSPHERE; POLYGLACTIN; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GUINEA PIG; HISTOPATHOLOGY; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; INDICATORS AND REAGENTS; LACTIC ACID; LUNG; MACROPHAGES; MALE; MICROBIAL SENSITIVITY TESTS; MICROSPHERES; MYCOBACTERIUM TUBERCULOSIS; POLYGLYCOLIC ACID; POLYMERS; RIFAMPIN; TUBERCULOSIS;

EID: 0034848118     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013094112861     Document Type: Article

References (22)

1. Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice
2. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs
3. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: A five-year follow-up report
4. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide
5. Side effects of drug regimens used in short course chemotherapy for pulmonary tuberculosis: A controlled study
6. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis
7. Tuftsin-bearing liposomes as rifampicin vehicles in treatment of tuberculosis in mice
8. Therapeutic efficacies of izoniasid and rifampicin encapsulated in lung-specific stealth liposomes agaist Mycobacterium tuberculosis infection induced in mice
9. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats
10. Should isoniazid be used in treatment of tuberculosis despite acquired isoniazid resistance
11. Efficacy of microencapsulated rifampicin in mycobacterium tuberculosis-infected mice
12. Use of microsphere technology for targeted delivery of rifampin to mycobacterium tuberculosis-infected macrophages
13. Animal model: Experimental airborne tuberculosis in the guinea pig
14. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization
15. Host-parasite relationships in experimental airborne tuberculosis II. Reproducible infection by means of an inoculum preserved at - 70 degrees C
16. Lower respiratory tract
17. A mathematical model for aerosol deposition in the respiratory tract of the guinea pig
18. Host-parasite relationships in experimental airborne tuberculosis. III. Relevance of microbial enumeration to acquired resistance in guinea pigs
19. Mycobacterial infection in guinea pigs
20. Guinea pig model of tuberculosis
21. Therapeutic uses of lung aerosols